The Value of Tranxemic Acid to Reduce Intraoperative Blood Loss During Elective Cesarean Sections in High Risk Women

• Status: Completed
• Trial end date: 2020-01-02
• Target enrollment: 0
• Participant gender: Female

Summary

A full medical history will be obtained from all participants. Obstetric ultrasonography and laboratory tests will be performed.According to group assignment, either 1 g(10 mL) tranexamic acid stored in a dry container at 15 °C-30 °C) diluted in 20 mL of 5% glucose or 30 mL of 5% glucose will be slowly administered intravenously 15 minutes before skin incision over a 5-minute period.

Following delivery, patients in both groups will receive an intravenous bolus of 5 IU oxytocin , 1 mL(0.2 mg) intramuscular ergometrine , and 20 IU oxytocin in 500 mL lactated Ringer's solution(infused at a rate of 125 mL/h)

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• • Grand multipara

• Multiple pregnancy

• Polyhydraminos (AFI is more than 24 cm).

• Placenta previa

• Gestational diabetes mellitus

• Preeclampsia

• Anemia complicating pregnancy (Hemoglobin is less than 11 gm/dl)

Exclusion Criteria:

• • Allergy to tranxemic acid.

• H/o suggestive of bleeding disorders

• previous history of deep vein thrombosis

• Abnormally invasive placenta

• Emergency cesarean sections

• Intraoprative complications during cesarean sections as uterine artery injury and broad ligamentary hematoma.